← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 29, 2026

Abivax S.A. (ABVX)

Healthcare • NASDAQ

$113.35

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

26.0/100

POOR BUSINESS

Abivax S.A. (ABVX) scores 26/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ABVX quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ABVX valuation analysis · → View full ABVX Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-73.8%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)

Operating Margin (Operational Efficiency):CRITICAL (-5,384.2%)

Return on Capital (Capital Efficiency):CRITICAL (-272.8%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

Abivax S.A. (ABVX) stock report — Zyberno Score 26/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:113.35

Market Cap:$8.90B

Valuation Multiples (3)

P/B Ratio:16.93x

P/S Ratio:1,685.95x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.31B

Price Action & Momentum (2)

12-1 Momentum:

+75.1%

📈 Click to view full ABVX Momentum analysis →

% of 52-Week High:81.5%

B. Profitability Assessment

Return Metrics (5)

ROE:

-73.8%

📊 Click to view full ABVX ROE analysis →

ROA:-57.5%

Roic:

-272.8%

📊 Click to view full ABVX ROIC analysis →

Reinvestment Rate:0.5%

Fundamental Growth Rate (g):-1.4%

Margin Analysis (3)

Operating Margin Ttm:-5,384.2%

Net Margin Ttm:-7,354.5%

Ebitda Margin:-5,360.7%

TTM Performance (2)

Operating Margin Ttm:-5,384.2%

Net Margin Ttm:-7,354.5%

Yield Metrics (2)

Earnings Yield:-$4.26

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:8.75x

Quick Ratio:8.75x

Cash Ratio:8.20x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x

Debt-to-Equity Ratio:0.00x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.20x

Times Interest Earned:-2.20

Capital Structure (4)

Working Capital:564,092,854.20

Cash And Cash Equivalents:596,977,849.00

Long Term Debt:$0.00

Net Debt:-$596.98M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $5.28M

Linear Growth: -50.0%

📊 Click to view full ABVX Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$284.29M

Bottom Line Performance (3)

-$388.33M

Income Before Tax:$0.00

Ebitda Ttm:-283,054,513.60

Operating Expenses (5)

Operating Expenses:0.00

R And D Expense:0.00

Sga Expense:0.00

Income Tax Expense:$6.76M

Interest Expense:129,107,862.20

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:0.0%

Ebitda Margin:-5,360.7%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$675.15M

Current Assets:$636.91M

Ppe Net:0.00

Goodwill:21,281,312.60

Intangible Assets:$7.63M

Liability Structure (4)

Total Liabilities:149,203,734.40

Current Liabilities:72,814,463.40

Long Term Debt:$0.00

Short Term Debt:$0.00

Equity & Capital (3)

Equity:$525.94M

Retained Earnings:$0.00

Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00

Inventory:0.00

Accounts Payable:27,022,495.20

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:0.00

C. Cash Flow Analysis

Operating Activities (2)

-$186.17M-$186.33M

Investment Activities (1)

Investing Cash Flow:$1.25M

Financing Activities (3)

Financing Cash Flow:-$9.05M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.83

-$4.83

Earnings Per Share Ttm:-$4.94

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.07

Operating Cash Flow Per Share:-$2.37

Book Value & Capital (2)

Book Value Per Share:$6.70

Cash Per Share:7.60

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x

Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x

Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x

Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:1,867.97

Cash Conversion Cycle:-3,865.97

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:40.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%

Fundamental Growth Rate (g):-1.4%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

C. Company Profile & Context

Corporate Information (6)

Symbol:ABVX

Company Name:Abivax S.A.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:high

Volume Category:N/A

Share Structure (3)

Shares Outstanding:78.54M

Shares Outstanding Basic:0

Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-29 18:28:44 UTC

Data Timestamp:2026-08-29T18:28:44.087998